FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: CYTOKINE RELEASE SYNDROME

1 INDICATIONS AND USEAGE
   1.1 Follicular Lymphoma

2 DOSAGE AND ADMINISTRATION
   2.1 Important Dosing Information
   2.2 Recommended Dosage
   2.3 Recommended Premedication and Prophylactic Medications
   2.4 Dosage Modifications for Adverse Reactions
   2.5 Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS
   5.1 Cytokine Release Syndrome
   5.2 Neurologic Toxicity
   5.3 Infections
   5.4 Cytopenias
   5.5 Tumor Flare
   5.6 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS
   6.1 Clinical Trials Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS
   8.1 Pregnancy
   8.2 Lactation
   8.3 Females and Males of Reproductive Potential
   8.4 Pediatric Use
   8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
   12.1 Mechanism of Action
   12.2 Pharmacodynamics
   12.3 Pharmacokinetics
   12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY
   13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME

Cytokine release syndrome (CRS), including serious or life-threatening reactions, can occur in patients receiving LUNSUMIO. Initiate treatment with the LUNSUMIO step-up dosing schedule to reduce the risk of CRS. Withhold LUNSUMIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.1 and 2.4) and Warnings and Precautions (5.1)].

1 INDICATIONS AND USAGE

1.1 Follicular Lymphoma

LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate [see Clinical Studies (14.1)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosing Information

- Administer LUNSUMIO to well-hydrated patients.
- Premedicate before each dose in Cycle 1 and Cycle 2 [see Dosage and Administration (2.2)].
- Administer only as an intravenous infusion through a dedicated infusion line. Do not use an in-line filter to administer LUNSUMIO. Drip chamber filters can be used to administer LUNSUMIO.
- LUNSUMIO should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as cytokine release syndrome and neurologic toxicity [see Warnings and Precautions (5.1 and 5.2)].

2.2 Recommended Dosage

The recommended dosage for LUNSUMIO is presented in Table 1.

Administer for 8 cycles, unless patients experience unacceptable toxicity or disease progression.

For patients who achieve a complete response, no further treatment beyond 8 cycles is required. For patients who achieve a partial response or have stable disease in response to treatment with LUNSUMIO after 8 cycles, an additional 9 cycles of treatment (17 cycles total) should be administered, unless a patient experiences unacceptable toxicity or disease progression.
Table 1. Recommended LUNSUMIO Dose and Schedule (21-Day Treatment Cycles)

<table>
<thead>
<tr>
<th>Day of Treatment</th>
<th>Dose of LUNSUMIO</th>
<th>Rate of Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1 Day 1</td>
<td>1 mg</td>
<td>Administer over a minimum of 4 hours.</td>
</tr>
<tr>
<td>Cycle 1 Day 8</td>
<td>2 mg</td>
<td></td>
</tr>
<tr>
<td>Cycle 1 Day 15</td>
<td>60 mg</td>
<td></td>
</tr>
<tr>
<td>Cycle 2 Day 1</td>
<td>60 mg</td>
<td>Administer over 2 hours if infusions from Cycle 1 were well-tolerated.</td>
</tr>
<tr>
<td>Cycles 3+ Day 1</td>
<td>30 mg</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Recommendations for Restarting Therapy with LUNSUMIO After Dose Delay

<table>
<thead>
<tr>
<th>Last Dose Administered</th>
<th>Time Since the Last Dose Administered</th>
<th>Action for Next Dose(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg Cycle 1 Day 1</td>
<td>1 to 2 weeks</td>
<td>Administer 2 mg (Cycle 1 Day 8), then resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than 2 weeks</td>
<td>Repeat 1 mg (Cycle 1 Day 1), then administer 2 mg (Cycle 1 Day 8) and resume the planned treatment schedule.</td>
</tr>
<tr>
<td>2 mg Cycle 1 Day 8</td>
<td>1 to 2 weeks</td>
<td>Administer 60 mg (Cycle 1 Day 15), then resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than 2 weeks</td>
<td>Repeat 2 mg (Cycle 1 Day 8), then administer 60 mg (Cycle 1 Day 15) and resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>to less than 6 weeks</td>
<td>Repeat 1 mg (Cycle 1 Day 1) and 2 mg (Cycle 1 Day 8), then administer 60 mg (Cycle 1 Day 15) and resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than or equal to 6 weeks</td>
<td>Repeat 1 mg (Cycle 1 Day 1) and 2 mg (Cycle 1 Day 8), then administer 60 mg (Cycle 1 Day 15) and resume the planned treatment schedule.</td>
</tr>
<tr>
<td>60 mg Cycle 1 Day 15</td>
<td>1 week to less than 6 weeks</td>
<td>Administer 60 mg (Cycle 2 Day 1), then resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than or equal to 6 weeks</td>
<td>Repeat 1 mg (Cycle 2 Day 1) and 2 mg (Cycle 2 Day 8), then administer 60 mg (Cycle 2 Day 15), followed by 30 mg (Cycle 3 Day 1) and then resume the planned treatment schedule.</td>
</tr>
<tr>
<td>60 mg Cycle 2 Day 1</td>
<td>3 weeks to less than 6 weeks</td>
<td>Administer 30 mg (Cycle 3 Day 1), then resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than or equal to 6 weeks</td>
<td>Repeat 1 mg (Cycle 3 Day 1) and 2 mg (Cycle 3 Day 8), then administer 30 mg (Cycle 3 Day 15)*, followed by 30 mg (Cycle 4 Day 1) and then resume the planned treatment schedule.</td>
</tr>
<tr>
<td>30 mg Cycle 3 onwards</td>
<td>3 weeks to less than 6 weeks</td>
<td>Administer 30 mg, then resume the planned treatment schedule.</td>
</tr>
<tr>
<td></td>
<td>Greater than or equal to 6 weeks</td>
<td>Repeat 1 mg on Day 1 and 2 mg on Day 8 during the next cycle, then administer 30 mg on Day 15*, followed by 30 mg on Day 1 of subsequent cycles.</td>
</tr>
</tbody>
</table>

* For the Day 1, Day 8, and Day 15 doses in the next cycle, administer premedication as per Table 3 for all patients.

2.3 Recommended Premedication and Prophylactic Medication

Premedication to reduce the risk of cytokine release syndrome and infusion-related reactions are outlined in Table 3 [see Warnings and Precautions (5.1)].
Table 3. Premedication to be Administered to Patients Prior to LUNSUMIO Infusion

<table>
<thead>
<tr>
<th>Treatment Cycle</th>
<th>Patients Requiring Premedication</th>
<th>Premedication</th>
<th>Dosage</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1 and Cycle 2</td>
<td>All patients</td>
<td>Corticosteroid</td>
<td>Dexamethasone 20 mg intravenous or methylprednisolone 80 mg intravenous</td>
<td>Complete at least 1 hour prior to infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antihistamine</td>
<td>Diphenhydramine hydrochloride 50 mg – 100 mg or equivalent oral or intravenous antihistamine</td>
<td>At least 30 minutes prior to infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antipyretic</td>
<td>Oral acetaminophen (500 mg – 1,000 mg)</td>
<td>At least 30 minutes prior to infusion</td>
</tr>
<tr>
<td>Cycles 3+</td>
<td>Patients who experienced any grade CRS with the previous dose</td>
<td>Corticosteroid</td>
<td>Dexamethasone 20 mg intravenous or methylprednisolone 80 mg intravenous</td>
<td>Complete at least 1 hour prior to infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antihistamine</td>
<td>Diphenhydramine hydrochloride 50 mg – 100 mg or equivalent oral or intravenous antihistamine</td>
<td>At least 30 minutes prior to infusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antipyretic</td>
<td>Oral acetaminophen (500 mg – 1,000 mg)</td>
<td>At least 30 minutes prior to infusion</td>
</tr>
</tbody>
</table>

2.4 Dosage Modifications for Adverse Reactions

See Tables 4 and 5 for the recommended dosage modifications for adverse reactions of CRS and neurologic toxicity, including Immune Effector Cell Associated Neurotoxicity (ICANS). See Table 6 for the recommended dosage modifications for other adverse reactions following administration of LUNSUMIO.

Dosage Modifications for Cytokine Release Syndrome

Identify cytokine release syndrome (CRS) based on clinical presentation [see Warnings and Precautions (5.1)]. Evaluate for and treat other causes of fever, hypoxia, and hypotension.

If CRS is suspected, withhold LUNSUMIO until CRS resolves, manage according to the recommendations in Table 4 and per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS.

Table 4. Recommendations for Management of Cytokine Release Syndrome

<table>
<thead>
<tr>
<th>Gradea</th>
<th>Presenting Symptoms</th>
<th>Actionsb</th>
</tr>
</thead>
</table>
| Grade 1 | Fever ≥ 100.4°F (38°C)c | • Withhold current infusion of LUNSUMIO and manage per current practice guidelines.  
  o If symptoms resolve, restart infusion at the same rate.  
  • Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.d  
  • Administer premedicationb prior to next dose of LUNSUMIO and monitor patient more frequently. |
**Presenting Symptoms**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Presenting Symptoms</th>
<th>Actions</th>
</tr>
</thead>
</table>
| Grade 2 | Fever $\geq 100.4^\circ \text{F} (38^\circ \text{C})$ with: Hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen by nasal cannula or blow-by. | Withhold current infusion of LUNSUMIO and manage per current practice guidelines.  
  o If symptoms resolve, restart infusion at 50% rate.  
  • Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.  
  • Administer premedication prior to next dose of LUNSUMIO and consider infusing the next dose at 50% rate.  
  • For the next dose of LUNSUMIO, monitor more frequently and consider hospitalization.  
  • Withhold current infusion of LUNSUMIO and manage per current practice guidelines.  
  • Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.  
  • Administer premedication prior to next dose of LUNSUMIO and consider infusing the next dose at 50% rate.  
  • For the next dose of LUNSUMIO, monitor more frequently and consider hospitalization.  
  • Withhold current infusion of LUNSUMIO and manage per current practice guidelines.  
  • Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.  
  • Administer premedication prior to next dose of LUNSUMIO and consider infusing the next dose at 50% rate.  
  • For the next dose of LUNSUMIO, monitor more frequently and consider hospitalization.  

**Recurrent Grade 2 CRS**

- Manage per Grade 3 CRS.

**Grade 3**

Fever $\geq 100.4^\circ \text{F} (38^\circ \text{C})$ with: Hypotension requiring a vasopressor (with or without vasopressin) and/or hypoxia requiring high flow oxygen by nasal cannula, face mask, non-rebreather mask, or Venturi mask.

- Withhold LUNSUMIO, manage per current practice guidelines and provide supportive therapy, which may include intensive care.
  - Ensure CRS symptoms are resolved for at least 72 hours prior to the next dose of LUNSUMIO.  
  - Administer premedication prior to next dose of LUNSUMIO and infuse the next dose at 50% rate.  
  - Hospitalize for the next dose of LUNSUMIO.

**Recurrent Grade 3 CRS**

- Permanently discontinue LUNSUMIO.
  - Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.

**Grade 4**

Fever $\geq 100.4^\circ \text{F} (38^\circ \text{C})$ with: Hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive pressure (e.g., CPAP, BiPAP, intubation and mechanical ventilation).

- Permanently discontinue LUNSUMIO.
  - Manage CRS per current practice guidelines and provide supportive therapy, which may include intensive care.

---

**Dosage Modifications for Neurologic Toxicity, including ICANS**

Management recommendations for neurologic toxicity, including ICANS, is summarized in Table 5. At the first sign of neurologic toxicity, including ICANS, withhold LUNSUMIO and...
consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care.

Table 5. Recommendations for Management of Neurologic Toxicity (including ICANS)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Severity¹,²</th>
<th>Actions</th>
</tr>
</thead>
</table>
| Neurologic Toxicity¹ (Including ICANS²) | Grade 2 | • Withhold LUNSUMIO until neurologic toxicity symptoms improve to Grade 1 or baseline for at least 72 hours.³  
• Provide supportive therapy. If ICANS, manage per current practice guidelines. |
| | Grade 3 | • Withhold LUNSUMIO until neurologic toxicity symptoms improve to Grade 1 or baseline for at least 72 hours.³  
• Provide supportive therapy, which may include intensive care, and consider neurology evaluation. If ICANS, manage per current practice guidelines.  
• If recurrence, permanently discontinue LUNSUMIO. |
| | Grade 4 | • Permanently discontinue LUNSUMIO.  
• Provide supportive therapy, which may include intensive care, and consider neurology evaluation. If ICANS, manage per current practice guidelines. |

¹ Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.  
² Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading for ICANS.  
³ See Table 2 for recommendations on restarting LUNSUMIO after dose delays [see Dosage and Administration (2.2)].

Table 6. Recommended Dosage Modification for Other Adverse Reactions

<table>
<thead>
<tr>
<th>Adverse Reactions¹</th>
<th>Severity¹</th>
<th>Actions</th>
</tr>
</thead>
</table>
| Infections [see Warnings and Precautions (5.3)] | Grades 1 – 4 | • Withhold LUNSUMIO in patients with active infection until the infection resolves.²  
• For Grade 4, consider permanent discontinuation of LUNSUMIO. |
| Neutropenia [see Warnings and Precautions (5.4)] | Absolute neutrophil count less than 0.5 × 10⁹/L | • Withhold LUNSUMIO until absolute neutrophil count is 0.5 × 10⁹/L or higher.² |
| Other Adverse Reactions [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)] | Grade 3 or higher | • Withhold LUNSUMIO until the toxicity resolves to Grade 1 or baseline.² |

¹ Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.  
² See Table 2 for recommendations on restarting LUNSUMIO after dose delays [see Dosage and Administration (2.2)].

2.5 Preparation and Administration

Preparation

Use aseptic technique to prepare LUNSUMIO.
• Inspect the vial visually for any particulate matter, prior to administration. Do not use if the solution is discolored, or cloudy, or if foreign particles are present.

• Determine the dose, the total volume of LUNSUMIO solution required, and the number of LUNSUMIO vials needed.

**Dilution**

1. Withdraw the volume from an infusion bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP equal to the volume of the LUNSUMIO required for the patient’s dose and discard. Only use infusion bags made of polyvinyl chloride (PVC) or polyolefin (PO) such as polyethylene (PE) and polypropylene.

2. Withdraw the required volume of LUNSUMIO from the vial using a sterile needle and syringe and dilute into the infusion bag of 0.9% Sodium Chloride Injection, USP or 0.45% Sodium Chloride Injection, USP according to Table 7. Discard any unused portion left in the vial.

**Table 7. Dilution of LUNSUMIO**

<table>
<thead>
<tr>
<th>Dose of LUNSUMIO</th>
<th>Volume of LUNSUMIO in 0.9% or 0.45% Sodium Chloride Solution</th>
<th>Size of Infusion Bag</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg</td>
<td>1 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td>2 mg</td>
<td>2 mL</td>
<td>50 mL or 100 mL</td>
</tr>
<tr>
<td>60 mg</td>
<td>60 mL</td>
<td>100 mL or 250 mL</td>
</tr>
<tr>
<td>30 mg</td>
<td>30 mL</td>
<td>50 mL, 100 mL, or 250 mL</td>
</tr>
</tbody>
</table>

3. Gently mix the intravenous bag by slowly inverting the bag. *Do not shake.*

4. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if visibly opaque particles, discoloration, or foreign particles are observed.

5. Apply the peel-off label from the package insert to the infusion bag.

6. Immediately use diluted LUNSUMIO infusion solution. If not used immediately, the diluted solution can be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours and at ambient temperature 9°C to 30°C (48°F to 86°F) for up to 16 hours. Prior to administration, ensure the infusion solution comes to reach room temperature.

**Administration**

• Administer as an intravenous infusion only.

• **Do not use an in-line filter to administer LUNSUMIO.**

• Do not mix LUNSUMIO with, or administer through the same infusion line, as other medicinal products.

• No incompatibilities have been observed between LUNSUMIO and intravenous infusion bags with product contacting materials of polyvinyl chloride (PVC), or polyolefins (PO).
such as polyethylene (PE) and polypropylene (PP). In addition, no incompatibilities have been observed with infusion sets or infusion aids with product contacting materials of PVC, PE, polyurethane (PUR), polybutadiene (PBD), silicone, acrylonitrile butadiene styrene (ABS), polycarbonate (PC), polyetherurethane (PEU), fluorinated ethylene propylene (FEP), or polytetrafluorethylene (PTFE), or with drip chamber filter membrane composed of polyamide (PA).

3 DOSAGE FORMS AND STRENGTHS

LUNSUMIO is a sterile, colorless solution available as:

- Injection: 1 mg/mL mosunetuzumab-axgb of solution in a single-dose vial
- Injection: 30 mg/30 mL (1 mg/mL) mosunetuzumab-axgb of solution in a single-dose vial

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Cytokine Release Syndrome

LUNSUMIO can cause cytokine release syndrome (CRS), including serious or life-threatening reactions [see Adverse Reactions (6.1)].

Cytokine release syndrome occurred in 39% of patients who received LUNSUMIO at the recommended dose in the clinical trial, with Grade 1 CRS occurring in 28%, Grade 2 in 15%, Grade 3 in 2%, and Grade 4 in 0.5% of patients. Recurrent CRS occurred in 11% of patients. Most patients experienced CRS following doses of 1 mg on Cycle 1 Day 1 (15%), 2 mg on Cycle 1 Day 8 (5%), and 60 mg on Cycle 1 Day 15 (33%). Five percent of patients experienced CRS after receiving 60 mg on Cycle 2 Day 1 with 1% of patients experiencing CRS following subsequent dosages of LUNSUMIO.

The median time to onset of CRS from the start of administration in Cycle 1 Day 1 was 5 hours (range: 1 hour to 3 days), Cycle 1 Day 8 was 28 hours (range: 5 hours to 3 days), Cycle 1 Day 15 was 25 hours (range: 0.1 hours to 16 days), and Cycle 2 Day 1 was 46 hours (range: 12 hours to 3 days). The median duration of CRS was 3 days (range: 1 to 29 days).

Clinical signs and symptoms of CRS included, but were not limited to, fever, chills, hypotension, tachycardia, hypoxia, and headache. Concurrent neurologic adverse reactions occurred in 6% of patients and included but were not limited to headache, confusional state, and anxiety.

Initiate therapy according to LUNSUMIO step-up dosing schedule to reduce the risk of CRS [see Dosage and Administration (2.3)]. Administer pretreatment medications to reduce the risk of CRS, ensure adequate hydration, and monitor patients following administration of LUNSUMIO accordingly.

At the first sign of CRS, immediately evaluate patients for hospitalization, manage per current practice guidelines and administer supportive care; withhold or permanently discontinue LUNSUMIO based on severity [see Dosage and Administration (2.4)].
Patients who experience CRS (or other adverse reactions that impair consciousness) should be evaluated and advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.

5.2 Neurologic Toxicity

LUNSUMIO can cause serious neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) [see Adverse Reactions (6.1)].

Neurologic toxicity occurred in 39% of patients who received LUNSUMIO at the recommended dose in the clinical trial, with Grade 3 neurologic toxicity occurring in 3% of patients. The most frequent neurologic toxicities were headache (21%), peripheral neuropathy (13%), dizziness (11%), and mental status changes (6%, including confusional state, disturbance in attention, cognitive disorder, delirium, encephalopathy, and somnolence). ICANS was reported in 1% of patients (Grade 1: 0.5%, Grade 2: 0.5%) who received LUNSUMIO at the recommended dose in the clinical trial.

Coadministration of LUNSUMIO with other products that cause dizziness or mental status changes may increase the risk of neurologic toxicity.

Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate the patient, consider neurology evaluation as appropriate, and provide supportive therapy based on severity; withhold or permanently discontinue LUNSUMIO based on severity and follow management recommendations [see Dosage and Administration (2.4)].

Patients who experience neurologic toxicity such as tremors, dizziness, insomnia, severe neurotoxicity, or any other adverse reactions that impair consciousness should be evaluated, including potential neurology evaluation, and patients at increased risk should be advised not to drive and to refrain from operating heavy or potentially dangerous machinery until resolution.

5.3 Infections

LUNSUMIO can cause serious or fatal infections [see Adverse Reactions (6.1)].

Among patients who received LUNSUMIO at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 17%, with Grade 3 or 4 infections in 14%, and fatal infections in 0.9% of patients. The most common Grade 3 or greater infections were pneumonia, sepsis, and upper respiratory tract infection.

Monitor patients for signs and symptoms of infection prior to and during treatment with LUNSUMIO and treat appropriately. LUNSUMIO should not be administered in the presence of active infection. Caution should be exercised when considering the use of LUNSUMIO in patients with a history of recurring or chronic infections (e.g., chronic, active Epstein-Barr Virus), with underlying conditions that may predispose to infections or who have had significant prior immunosuppressive treatment. Administer prophylactic antimicrobials according to guidelines.

Withhold LUNSUMIO or consider permanent discontinuation of LUNSUMIO based on severity [see Dosage and Administration (2.4)].
5.4 Cytopenias

LUNSUMIO can cause serious or severe cytopenias, including neutropenia, anemia, and thrombocytopenia [see Adverse Reactions (6.1)].

Among patients who received the recommended dosage in the clinical trial, Grade 3 or 4 decreased neutrophils occurred in 38%, decreased hemoglobin in 19%, and decreased platelets in 12% of patients. Grade 4 decreased neutrophils occurred in 19% and decreased platelets in 5% of patients. Febrile neutropenia occurred in 2%.

Monitor complete blood counts throughout treatment. Based on the severity of cytopenias, temporarily withhold, or permanently discontinue LUNSUMIO. Consider prophylactic granulocyte colony-stimulating factor administration as applicable [see Dosage and Administration (2.4)].

5.5 Tumor Flare

LUNSUMIO can cause serious or severe tumor flare [see Adverse Reactions (6.1)].

Among patients who received LUNSUMIO at the recommended dosage in the clinical trial, tumor flare occurred in 4% of patients. Manifestations included new or worsening pleural effusions, localized pain and swelling at the sites of lymphoma lesions, and tumor inflammation.

Patients with bulky tumors or disease located in close proximity to airways or a vital organ should be monitored closely during initial therapy. Monitor for signs and symptoms of compression or obstruction due to mass effect secondary to tumor flare. If compression or obstruction develops, institute standard treatment of these complications.

5.6 Embryo-Fetal Toxicity

Based on its mechanism of action, LUNSUMIO may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LUNSUMIO and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

- Cytokine Release Syndrome [see Warnings and Precautions (5.1)]
- Neurologic Toxicity [see Warnings and Precautions (5.2)]
- Infections [see Warnings and Precautions (5.3)]
- Cytopenias [see Warnings and Precautions (5.4)]
- Tumor Flare [see Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to LUNSUMIO as a single agent in GO29781 in 218 patients with hematologic
malignancies in an open-label, multicenter, multi-cohort study. Patients received step-up doses of 1 mg on Cycle 1 Day 1 and 2 mg on Cycle 1 Day 8, followed by 60 mg on Cycle 1 Day 15, and 60 mg on Cycle 2 Day 1, then 30 mg every 3 weeks in subsequent cycles. A treatment cycle was 21 days. Among 218 patients who received LUNSUMIO, 52% were exposed for at least 8 cycles and 8% were exposed for 17 cycles.

In this pooled safety population, the most common (≥ 20%) adverse reactions were cytokine release syndrome (39%), fatigue (36%), rash (34%), pyrexia (24%), and headache (21%). The most common Grade 3 to 4 laboratory abnormalities (≥ 10%) were decreased lymphocyte count (92%), decreased phosphate (41%), increased glucose (40%), decreased neutrophil count (38%), increased uric acid (15%), decreased white blood cell count (22%), decreased hemoglobin (19%), and decreased platelets (12%).

Relapsed or Refractory Follicular Lymphoma

GO29781

The safety of LUNSUMIO was evaluated in GO29781, an open-label, multicenter, multi-cohort study which included a cohort of 90 patients with relapsed or refractory follicular lymphoma (FL) [see Clinical Studies (14)]. In this cohort, patients with relapsed or refractory FL were required to have received at least two prior lines of systemic therapy, including an anti-CD20 monoclonal antibody and an alkylating agent. Patients received step-up doses of 1 mg on Cycle 1 Day 1 and 2 mg on Cycle 1 Day 8, followed by 60 mg on Cycle 1 Day 15 and 60 mg on Cycle 2 Day 1, then 30 mg every 3 weeks in subsequent cycles. A treatment cycle was 21 days. The median number of cycles was 8 (range: 1 – 17). In the relapsed or refractory FL cohort, 77% were exposed for at least 8 cycles and 12% were exposed for 17 cycles.

The median age of the patients who received LUNSUMIO in the relapsed or refractory FL cohort was 60 years (range: 29 to 90 years), 61% were male, 82% were White, 4% were Black or African American, 9% were Asian, and 8% were Hispanic or Latino.

Serious adverse reactions occurred in 47% of patients who received LUNSUMIO. Serious adverse reactions in ≥ 2% of patients included cytokine release syndrome, infection (including urinary tract infection, sepsis, pneumonia, EBV viremia, and COVID-19), renal insufficiency, pyrexia, and tumor flare.

Permanent discontinuation of LUNSUMIO due to an adverse reaction occurred in 3% of patients. Adverse reactions resulting in permanent discontinuation of LUNSUMIO included cytokine release syndrome and EBV viremia.

Dosage interruptions of LUNSUMIO due to an adverse reaction occurred in 37% of patients. Adverse reactions which required dosage interruption in ≥ 5% of patients included neutropenia, infection, and cytokine release syndrome.

Table 8 summarizes the adverse reactions in patients with relapsed or refractory FL in GO29781.
Table 8. Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory FL Who Received LUNSUMIO in GO29781

<table>
<thead>
<tr>
<th>Adverse Reaction¹</th>
<th>LUNSUMIO (N = 90)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades (%)</td>
<td>Grade 3 or 4 (%)</td>
<td></td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytokine release syndrome</td>
<td>44</td>
<td>2.2</td>
<td></td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue²</td>
<td>42</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Pyrexia</td>
<td>29</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td>Edema³</td>
<td>17</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td>13</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash⁴</td>
<td>39</td>
<td>4.4⁰</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td>21</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dry skin</td>
<td>16</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Skin exfoliation</td>
<td>10</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Nervous system</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache⁵</td>
<td>32</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy⁶</td>
<td>20</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dizziness⁷</td>
<td>12</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal pain⁸</td>
<td>28</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>11</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Respiratory, thoracic, and mediastinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cough⁹</td>
<td>22</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Dyspnea¹⁰</td>
<td>11</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>17</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>17</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Abdominal pain¹¹</td>
<td>12</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td><strong>Infections</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upper respiratory tract infection¹²</td>
<td>14</td>
<td>2.2⁰</td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection¹³</td>
<td>10</td>
<td>1.1⁰</td>
<td></td>
</tr>
<tr>
<td><strong>Psychiatric disorder</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>12</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

¹ Adverse reactions were graded based on CTCAE Version 4.0, with the exception of CRS, which was graded per ASTCT 2019 criteria
² Fatigue includes fatigue, asthenia, and lethargy
³ Edema includes edema, edema peripheral, peripheral swelling, face edema, swelling face, pulmonary edema, fluid overload, and fluid retention
⁴ Rash includes rash, rash erythematous, exfoliative rash, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, erythema, palmar erythema, dermatitis, and dermatitis acneiform
⁵ Headache includes headache and migraine
⁶ Peripheral neuropathy includes peripheral neuropathy, peripheral sensory neuropathy, paresthesia, dysaesthesia, hypoesthesia, burning sensation, and neuralgia
⁷ Dizziness includes dizziness and vertigo
⁸ Musculoskeletal pain includes muscle pain and musculoskeletal pain
⁹ Cough includes cough and bronchitis
¹⁰ Dyspnea includes dyspnea and shortness of breath
¹¹ Abdominal pain includes abdominal pain and acute abdomen
¹² Upper respiratory tract infection includes upper respiratory tract infection and pharyngitis
¹³ Urinary tract infection includes urinary tract infection and cystitis

Reference ID: 5099541
Clinically relevant adverse reactions in <10% of patients who received LUNSUMIO included pneumonia, sepsis, COVID-19, EBV viremia, mental status changes, tumor lysis syndrome, renal insufficiency, anxiety, motor dysfunction (including ataxia, gait disturbance and tremor), and tumor flare.

Table 9 summarizes the laboratory abnormalities in patients with relapsed or refractory FL in GO29781.

Table 9. Select Laboratory Abnormalities (≥20%) That Worsened from Baseline in Patients with Relapsed or Refractory FL Who Received LUNSUMIO in GO29781

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>LUNSUMIO¹</th>
<th>All Grades (%)</th>
<th>Grade 3 or 4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocyte count decreased</td>
<td>100</td>
<td></td>
<td>98</td>
</tr>
<tr>
<td>Hemoglobin decreased</td>
<td>68</td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>White blood cells decreased</td>
<td>60</td>
<td></td>
<td>13</td>
</tr>
<tr>
<td>Neutrophils decreased</td>
<td>58</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Platelets decreased</td>
<td>46</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td><strong>Chemistry</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphate decreased</td>
<td>78</td>
<td></td>
<td>46</td>
</tr>
<tr>
<td>Glucose increased</td>
<td>42</td>
<td></td>
<td>42</td>
</tr>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>39</td>
<td></td>
<td>4.4</td>
</tr>
<tr>
<td>Gamma-glutamyl transferase increased</td>
<td>34</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Magnesium decreased</td>
<td>34</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Potassium decreased</td>
<td>33</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>32</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Uric acid increased</td>
<td>22</td>
<td></td>
<td>22</td>
</tr>
</tbody>
</table>

¹The denominator used to calculate the rate varied from 72 to 90 based on the number of patients with a baseline value and at least one post-treatment value.
7 DRUG INTERACTIONS

Effect of LUNSUMIO on CYP450 Substrates

LUNSUMIO causes release of cytokines [see Clinical Pharmacology (12.2)] that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP450 substrates. Increased exposure of CYP450 substrates is more likely to occur after the first dose of LUNSUMIO on Cycle 1 Day 1 and up to 14 days after the second 60 mg dose on Cycle 2 Day 1 and during and after CRS [see Warnings and Precautions (5.1)]. Monitor for toxicity or concentrations of drugs that are CYP450 substrates where minimal concentration changes may lead to serious adverse reactions. Consult the concomitant CYP450 substrate drug prescribing information for recommended dosage modification.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on the mechanism of action, LUNSUMIO may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of LUNSUMIO in pregnant women to evaluate for a drug-associated risk. No animal reproductive or developmental toxicity studies have been conducted with mosunetuzumab-axgb.

Mosunetuzumab-axgb causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on expression of CD20 on B-cells and the finding of B-cell depletion in non-pregnant animals, mosunetuzumab-axgb can cause B-cell lymphocytopenia in infants exposed to mosunetuzumab-axgb in-utero. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, LUNSUMIO has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% – 4% and 15% – 20%, respectively.

8.2 Lactation

Risk Summary

There is no information regarding the presence of mosunetuzumab-axgb in human milk, the effect on the breastfed child, or milk production. Because human IgG is present in human milk, and there is potential for mosunetuzumab-axgb absorption leading to B-cell depletion, advise women not to breastfeed during treatment with LUNSUMIO and for 3 months after the last dose.

8.3 Females and Males of Reproductive Potential

LUNSUMIO may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating LUNSUMIO.
Contraception

Females
Advise females of reproductive potential to use effective contraception during treatment with LUNSUMIO and for 3 months after the last dose.

8.4 Pediatric Use
The safety and efficacy of LUNSUMIO have not been established in pediatric patients.

8.5 Geriatric Use
Among the 90 patients with relapsed or refractory follicular lymphoma treated with LUNSUMIO, 33% were 65 years of age or older, and 8% were 75 years of age or older. There is an insufficient number of patients 65 years of age or older and 75 years of age or older to assess whether there are differences in safety or effectiveness in patients 65 years of age and older compared to younger adult patients.

11 DESCRIPTION
Mosunetuzumab-axgb is a bispecific CD20-directed CD3 T-cell engager. It is a humanized monoclonal anti-CD20xCD3 T-cell-dependent bispecific antibody of the immunoglobulin G1 (IgG1) isotype. Mosunetuzumab-axgb is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. The approximate molecular weight is 146 kDa.

LUNSUMIO (mosunetuzumab-axgb) injection is a sterile, preservative-free, colorless solution for intravenous use.

Each single-dose vial contains a 1 mL solution of mosunetuzumab-axgb (1 mg), acetic acid (0.4 mg), histidine (1.6 mg), methionine (1.5 mg), polysorbate 20 (0.6 mg), sucrose (82.1 mg), and Water for Injection, USP. The pH is 5.8.

Each single-dose vial contains a 30 mL solution of mosunetuzumab-axgb (30 mg), acetic acid (12.8 mg), histidine (46.6 mg), methionine (44.8 mg), polysorbate 20 (18 mg), sucrose (2,462.4 mg), and Water for Injection, USP. The pH is 5.8.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Mosunetuzumab-axgb is a T-cell engaging bispecific antibody that binds to the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and some healthy B-lineage cells.

In vitro, mosunetuzumab-axgb activated T-cells, caused the release of proinflammatory cytokines, and induced lysis of B-cells.

12.2 Pharmacodynamics
After administration of the recommended dosage of LUNSUMIO, peripheral B-cell counts decreased to undetectable levels (< 5 cells/microliter) in most patients (92%) by Cycle 2 Day 1 and the depletion was sustained at later cycles including at Cycle 4 and Cycle 8.

LUNSUMIO caused hypogammaglobulinemia (defined as IgG levels < 500 mg/dL). Among 67 patients with baseline IgG levels ≥ 500 mg/dL, 40% had their IgG level decreased to < 500 mg/dL after administration of the recommended dosage of LUNSUMIO.
Plasma concentrations of cytokines (IL-2, IL-6, IL-10, TNF-α, and IFN-γ) were measured, and transient elevation of cytokines were observed at doses of 0.4 mg and above. After administration of the recommended dosage of LUNSUMIO, the highest elevation of cytokines was observed within 24 hours after first dose on Cycle 1 Day 1 and after the first 60 mg dose on Cycle 1 Day 15. The elevated cytokine levels generally returned to baseline prior to the next infusion on Cycle 1 Day 8 and on Cycle 2 Day 1. Limited data is available in subsequent treatment cycles.

12.3 Pharmacokinetics

Mosunetuzumab-axgb PK exposure increased proportionally over a dose range from 0.2 mg to 60 mg (0.007 to 2 times the recommended treatment dosage). PK exposures are summarized for the recommended dosage of LUNSUMIO in Table 10 and Figure 1.

Table 10. Exposure Parameters of Mosunetuzumab-axgb

<table>
<thead>
<tr>
<th></th>
<th>AUC (day·μg/mL)¹</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (μg/mL)¹</th>
<th>C&lt;sub&gt;trough&lt;/sub&gt; (μg/mL)¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle 1 (0 – 21 days)</td>
<td>35.2 (36.6)</td>
<td>11.1 (36.7)</td>
<td>2.57 (54.0)</td>
</tr>
<tr>
<td>Cycle 2 (21 – 42 days)</td>
<td>90.3 (48.5)</td>
<td>13.6 (37.7)</td>
<td>1.97 (83.1)</td>
</tr>
<tr>
<td>Steady state²</td>
<td>52.9 (40.7)</td>
<td>7.02 (37.9)</td>
<td>1.29 (59.9)</td>
</tr>
</tbody>
</table>

¹ Values are geometric mean with geometric CV%
² Steady state values are approximated at Cycle 4 (63 – 84 days)

Figure 1. Model-Predicted Mosunetuzumab Concentration Time Profile

Distribution

The mean (CV%) volume of distribution of mosunetuzumab-axgb was 5.49 L (31%).

Reference ID: 5099541
Elimination
The steady-state geometric mean (CV%) terminal elimination half-life of mosunetuzumab-axgb was 16.1 (17.3%) days. The geometric mean (CV%) clearance at baseline and at steady state are 1.08 L/day (63%) and 0.584 L/day (18%), respectively.

Specific Populations
There were no clinically significant differences in the pharmacokinetics of mosunetuzumab-axgb based on age (19 to 96 years), sex, race (Asian and Non-Asian), ethnicity (Hispanic/Latino and not Hispanic/Latino), mild or moderate renal impairment (estimated Creatinine clearance [CrCL] by Cockcroft-Gault formula: 30 to 89 mL/min), or mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST).

The effects of severe renal impairment (CrCL 15 to 29 mL/min) or moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of mosunetuzumab-axgb are unknown.

Drug Interaction Studies
No clinical studies evaluating the drug interaction potential of mosunetuzumab-axgb have been conducted.

12.6 Immunogenicity
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the study described below with the incidence of anti-drug antibodies in other studies, including those of mosunetuzumab-axgb.

During treatment in Study GO29781 (up to 12 months) [see Clinical Studies (14)], using an enzyme-linked immunosorbent assay (ELISA), no patients (N = 418) treated with LUNSUMIO developed anti-mosunetuzumab-axgb antibodies. Based on these data, the clinical relevance of anti-mosunetuzumab-axgb antibodies could not be assessed.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No carcinogenicity or genotoxicity studies have been conducted with mosunetuzumab-axgb. No dedicated studies have been conducted to evaluate the effects of mosunetuzumab-axgb on fertility. No adverse effects on either male or female reproductive organs were identified in a 26-week repeat dose chronic toxicity study in sexually mature cynomolgus monkeys.

14 CLINICAL STUDIES
The efficacy of LUNSUMIO was evaluated in an open-label, multicenter, multi-cohort study (GO29781, NCT02500407) in patients with relapsed or refractory follicular lymphoma (FL) who had received at least two prior therapies, including an anti-CD20 monoclonal antibody and an alkylating agent. The study excluded patients with active infections, history of autoimmune disease, prior allogeneic transplant, or any history of CNS lymphoma or CNS disorders.
Patients received step-up doses of 1 mg on Cycle 1 Day 1 and 2 mg on Cycle 1 Day 8, followed by 60 mg on Cycle 1 Day 15, and 60 mg on Cycle 2 Day 1, then 30 mg every 3 weeks in subsequent cycles. A treatment cycle was 21 days. LUNSUMIO was administered for 8 cycles unless patients experienced progressive disease or unacceptable toxicity. After 8 cycles, patients with a complete response discontinued therapy; patients with a partial response or stable disease continued treatment up to 17 cycles, unless patients experienced progressive disease or unacceptable toxicity.

Among the 90 patients with relapsed or refractory FL, the median age was 60 years (range: 29 to 90 years), 33% were 65 years of age or older, 61% were male, 82% were White, 9% were Asian, 4% were Black or African American, and 8% were Hispanic or Latino. A total of 77% of patients had Stage III-IV disease, 34% had bulky disease, and all patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The median number of prior therapies was 3 (range: 2 to 10), with 38% receiving 2 prior therapies, 31% receiving 3 prior therapies, and 31% receiving more than 3 prior therapies.

Seventy-nine percent of patients were refractory to prior anti-CD20 monoclonal antibody therapy, 53% were refractory to both anti-CD20 monoclonal antibody and alkylator therapy, 9% received prior rituximab plus lenalidomide therapy, 21% received prior autologous stem cell transplant, and 3% received prior CAR T therapy. Fifty-two percent of patients had progression of disease within 24 months of first systemic therapy.

Efficacy was established on the basis of objective response rate (ORR) and duration of response (DOR) as assessed by an independent review facility according to standard criteria for NHL (Cheson 2007). The median follow-up for DOR was 14.9 months. The efficacy results are summarized in Table 11.

<table>
<thead>
<tr>
<th>Response</th>
<th>LUNSUMIO N = 90</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Objective response rate (ORR), n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
</tr>
<tr>
<td>Complete response rate (CR), n (%)</td>
<td>54 (60)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(49, 70)</td>
</tr>
<tr>
<td>Partial response rate (PR), n (%)</td>
<td>18 (20)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(12, 30)</td>
</tr>
<tr>
<td><strong>Duration of Response (DOR)</strong></td>
<td>N = 72</td>
</tr>
<tr>
<td>Median DOR¹, months (95% CI)</td>
<td>22.8 (10, NR)</td>
</tr>
<tr>
<td>Rate of Continued Response²</td>
<td></td>
</tr>
<tr>
<td>At 12 months, %</td>
<td>62</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(50, 74)</td>
</tr>
<tr>
<td>At 18 months, %</td>
<td>57</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(44, 70)</td>
</tr>
</tbody>
</table>

CI = confidence interval; NR = not reached

¹ DOR is defined as the time from the initial occurrence of a documented PR or CR until the patient experienced an event (documented disease progression or death due to any cause, whichever occurs first), among patients who achieved a PR or CR.

² Kaplan-Meier estimate.
The median time to first response was 1.4 months (range: 1.1 to 8.9).

16 HOW SUPPLIED/STORAGE AND HANDLING

LUNSUMIO (mosunetuzumab-axgb) injection is a sterile, colorless, preservative-free solution supplied as follows:

- One 1 mg/mL single-dose vial in a carton (NDC 50242-159-01)
- One 30 mg/30 mL (1 mg/mL) single-dose vial in a carton (NDC 50242-142-01).

Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Cytokine Release Syndrome (CRS) – Discuss the signs and symptoms associated with CRS, including fever, chills, hypotension, tachycardia, hypoxia, and headache. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. Advise patients who experience symptoms that impair consciousness not to drive and refrain from operating heavy or potentially dangerous machinery until events resolve [see Warnings and Precautions (5.1)].

Neurologic Toxicity – Discuss the signs and symptoms associated with neurologic toxicity, including ICANS, headache, peripheral neuropathy, dizziness, or mental status changes. Advise patients to immediately contact their healthcare provider if they experience any signs or symptoms of neurologic toxicity. Advise patients who experience neurologic toxicity that impairs consciousness to refrain from driving or operating heavy or potentially dangerous machinery until neurologic toxicity resolves [see Warnings and Precautions (5.2)].

Infections – Discuss the signs or symptoms associated with infection [see Warnings and Precautions (5.3)].

Cytopenias – Discuss the signs and symptoms associated with cytopenias, including neutropenia and febrile neutropenia, anemia, and thrombocytopenia [see Warnings and Precautions (5.4)].

Tumor Flare – Inform patients of the potential risk of tumor flare reaction and to report any signs and symptoms associated with this event to their healthcare provider for evaluation [see Warnings and Precautions (5.5)].

Embryo-Fetal Toxicity – Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider if they are pregnant or become pregnant [see Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with LUNSUMIO and for 3 months after the last dose [see Use in Specific Populations (8.3)].

Lactation – Advise women not to breastfeed during treatment with LUNSUMIO and for 3 months after the last dose [see Use in Specific Populations (8.2)].
What is the most important information I should know about LUNSUMIO?

LUNSUMIO may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with LUNSUMIO, and can also be severe or life-threatening.

Get medical help right away if you develop any signs or symptoms of CRS at any time, including:

- fever of 100.4°F (38°C) or higher
- chills
- low blood pressure
- fast or irregular heartbeat
- tiredness or weakness
- difficulty breathing
- headache
- confusion
- feeling anxious
- dizziness or light-headedness
- nausea
- vomiting

Due to the risk of CRS, you will receive LUNSUMIO on a “step-up dosing schedule”.

- The step-up dosing schedule is when you receive smaller “step-up” doses of LUNSUMIO on Day 1 and Day 8 of your first cycle of treatment.
- You will receive a higher dose of LUNSUMIO on Day 15 of your first cycle of treatment.
- If your dose of LUNSUMIO is delayed for any reason, you may need to repeat the “step-up dosing schedule.”
- Before each dose in Cycle 1 and Cycle 2, you will receive medicines to help reduce your risk of CRS.

See “How will I receive LUNSUMIO?” for more information about how you will receive LUNSUMIO.

Your healthcare provider will check you for CRS during treatment with LUNSUMIO and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with LUNSUMIO, if you have severe side effects.

See “What are the possible side effects of LUNSUMIO?” for more information about side effects.

What is LUNSUMIO?

LUNSUMIO is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer.

It is not known if LUNSUMIO is safe and effective in children.

Before receiving LUNSUMIO, tell your healthcare provider about all of your medical conditions, including if you:

- have ever had an infusion reaction after receiving LUNSUMIO.
- have an infection or have had an infection in the past which lasted a long time or keeps coming back.
- have or had Epstein-Barr Virus.
- are pregnant or plan to become pregnant. LUNSUMIO may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LUNSUMIO.

Females who are able to become pregnant:

- your healthcare provider should do a pregnancy test before you start treatment with LUNSUMIO.
- you should use an effective method of birth control during your treatment and for 3 months after the last dose of LUNSUMIO.

- are breastfeeding or plan to breastfeed. It is not known if LUNSUMIO passes into your breast milk. Do not breastfeed during treatment and for 3 months after the last dose of LUNSUMIO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
**How will I receive LUNSUMIO?**

- LUNSUMIO will be given to you by your healthcare provider by infusion through a needle placed in a vein (intravenous infusion).
- After you complete the weekly “step-up dosing schedule” in Cycle 1, LUNSUMIO is given every 21 days.
- After Cycle 1 and Cycle 2, your healthcare provider will decide if you need to continue to take other medicines to help reduce side effects from LUNSUMIO during future cycles.
- Your healthcare provider will decide how many treatment cycles you will receive of LUNSUMIO.

See “What is the most important information I should know about LUNSUMIO?" for more information about how you will receive LUNSUMIO.

**What should I avoid while receiving LUNSUMIO?**

*Do not* drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems.

See “What is the most important information I should know about LUNSUMIO?” and “What are the possible side effects of LUNSUMIO?” for more information about signs and symptoms of CRS and neurologic problems.

**What are the possible side effects of LUNSUMIO?**

*LUNSUMIO may cause serious side effects, including:*

See “What is the most important information I should know about LUNSUMIO?”

- **Neurologic problems.** Your healthcare provider will check you for neurologic problems during treatment with LUNSUMIO. Your healthcare provider may also refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems during or after treatment with LUNSUMIO, including:
  - headache
  - numbness and tingling of the arms, legs, hands, or feet
  - dizziness
  - confusion and disorientation
  - difficulty paying attention or understanding things
  - forgetting things or forgetting who or where you are
  - trouble speaking, reading, or writing
  - sleepiness or trouble sleeping
  - tremors
  - loss of consciousness
  - seizures
  - muscle problems or muscle weakness
  - loss of balance or trouble walking

- **Serious infections.** LUNSUMIO can cause serious infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with LUNSUMIO, including:
  - fever of 100.4°F (38°C) or higher
  - cough
  - chest pain
  - tiredness
  - shortness of breath
  - painful rash
  - sore throat
  - pain during urination
  - feeling weak or generally unwell

- **Low blood cell counts.** Low blood cell counts are common during treatment with LUNSUMIO and can also be severe.

  Your healthcare provider will check your blood cell counts during treatment with LUNSUMIO. LUNSUMIO may cause the following low blood cell counts:
  - low white blood cell counts (neutropenia). Low white blood cells can increase your risk for infection.
  - low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath.
  - low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems.
• Growth in your tumor or worsening of tumor related problems (Tumor flare). LUNSUMIO may cause serious or severe worsening of your tumor.

Tell your healthcare provider if you develop any of these signs or symptoms of tumor flare during your treatment with LUNSUMIO: tender or swollen lymph nodes, chest pain, cough, trouble breathing, and pain or swelling at the site of the tumor.

Your healthcare provider may temporarily stop or permanently stop treatment with LUNSUMIO if you develop severe side effects.

The most common side effects of LUNSUMIO include: tiredness, rash, fever, and headache.

The most common severe abnormal lab test results with LUNSUMIO include: decreased phosphate, increased glucose, and increased uric acid levels.

These are not all the possible side effects of LUNSUMIO.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of LUNSUMIO.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about LUNSUMIO that is written for health professionals.

What are the ingredients in LUNSUMIO?
Active ingredient: mosunetuzumab-axgb
Inactive ingredients: acetic acid, histidine, methionine, polysorbate 20, sucrose, and Water for Injection

Manufactured by: Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990
U.S. License No.: 1048
LUNSUMIO is a trademark of Genentech, Inc.
For more information, call 1-844-832-3687 or go to www.LUNSUMIO.com.

This Medication Guide has been approved by the U.S. Food and Drug Administration. Issued: 12/2022